ANXIETY REDUCTION AMONG BREAST-CANCER SURVIVORS RECEIVING HYPNOTIC RELAXATION THERAPY FOR HOT FLASHES

ALISA J. JOHNSON  
Baylor University, Waco, Texas, USA

JOEL MARCUS  
Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA

KIMBERLY HICKMAN  
Baylor University, Waco, Texas, USA

DEBRA BARTON  
University of Michigan School of Nursing, Ann Arbor, USA

GARY ELKINS  
Baylor University, Waco, Texas, USA

Abstract: Anxiety is common among breast-cancer survivors. This analysis examined the effect of a hypnotic relaxation therapy, developed to reduce hot flashes, on anxiety levels of female breast-cancer survivors. Anxiety was assessed using a numeric analog scale and the Hospital Anxiety and Depression Scale-Anxiety subscale. Significant reductions in anxiety were found from pre- to postintervention for each weekly session and were predictive of overall reductions in anxiety from baseline to after the last intervention. In this analysis, hypnotizability did not significantly predict for anxiety reductions measured before and after each session or from baseline to exit. These data provide initial support for the use of hypnotic relaxation therapy to reduce anxiety among breast-cancer survivors.
Breast cancer is the most common cancer among women in the United States with more than 2.9 million cases reported (American Cancer Society, 2013; U. S. Cancer Statistics Working Group, 2013). The American Cancer Society estimated that more than 230,000 women were diagnosed with breast cancer in 2013 alone. Due to improvements in cancer detection and treatments, survival rates for breast-cancer patients have increased; thus, women with breast cancer now comprise the largest group of cancer survivors in the United States (American Cancer Society, 2013; Berry et al., 2005; Smith, Singh-Carlson, Downie, Payeur, & Wai, 2011). Therefore, it is imperative to investigate the comorbidities of breast-cancer survivorship, including anxiety, and possible treatments.

Anxiety is a common symptom associated with cancer diagnosis, treatment, and survivorship (Hodgkinson et al., 2007). A recent review found that anxiety is ubiquitous in women receiving treatment for breast cancer and that certain types of treatment, such as chemotherapy and mastectomy, are associated with greater levels of anxiety (Lim, Devi, & Ang, 2011). It has been reported that fear of cancer recurrence affects 33% to 56% of cancer patients and is associated with psychological distress (Lebel, Beattie, Arès, & Bielajew, 2013). In a study examining quality of life in long-term breast-cancer survivors, 71% reported anxiety and fear of cancer recurrence (Gotay & Muraoka, 1998). Boyes, Girgis, D’Este, and Zucca (2011) reported that 30% of breast-cancer survivors experienced clinical levels of anxiety up to 6 months after treatment ended. It has been shown that 80% of women with breast cancer report significant distress (Elkins, 2014b). One source of this distress is hot flashes. Hot flashes are linked to reduced quality of life and increased distress among breast-cancer patients (Carpenter, Johnson, Wagner, & Andrykowki, 2002). The distress caused by hot flashes increases the risk for anxiety in patients already prone to experience high levels of anxiety. It has been noted that, among cancer patients, anxiety is particularly difficult to treat with traditional psychopharmacological and therapeutic means due to possible drug interactions and side effects (Schernhammer, Haidinger, Waldhör, & Vutuc, 2009). Therefore, alternatives to pharmacological treatments are needed. Mind-body therapies are increasingly being researched as possible solutions (Schernhammer et al., 2009). The increasing use of complementary and alternative medicine (CAM) for oncology symptoms indicates that interest in nonpharmacological methods of treatment is helpful and desired (Booth-LaForce et al., 2010).

Hypnosis is an intervention that has been shown to be effective in treating anxiety related to various medical conditions, including hemodialysis, atypical cardiac disorder, bone-marrow biopsies, colonoscopy, postoperative surgery, emergency dental extraction, and large-core breast biopsy (Chan, 2012; Elkins et al., 2006; Gow, 2006;
Lang et al., 2006; Massarini, Rovetto, & Tagliaferri, 2005; Snow et al., 2012; Untas et al., 2013). Studies investigating the use of hypnosis in controlling anxiety in cancer patients found that hypnosis interventions significantly decreased anxiety (Genuis, 1995). Research has shown that hypnosis is likely efficacious in the treatment of both state and trait anxiety; however, it is acknowledged that further randomized controlled trials are needed to solidify findings (Coelho, Canter, & Ernst, 2007; Hammond, 2010). Overall, the current literature supports the use of hypnosis as a means of decreasing anxiety in a variety of health conditions. However, there remains a lack of information regarding the effectiveness of a hypnotic intervention on anxiety among breast-cancer survivors.

The current analysis utilizes data from a larger study in which we examined hypnotic relaxation therapy (Elkins, 2014a) as a treatment for hot flashes among breast-cancer survivors (Elkins et al., 2008). The larger study demonstrated hot flashes decreased by an average of 68% over baseline. The full study methods, a description of the baseline sample, and the primary outcomes have been reported elsewhere (Elkins et al., 2011, 2008). The purpose of this secondary analysis was to investigate the effectiveness of hypnotic relaxation therapy (HRT) on self-reported anxiety among breast-cancer survivors. These data have not been previously analyzed or reported.

**Method**

**Participants**

Participants were recruited from the Scott and White Cancer Institute in Temple, Texas. After informed consent, recruited participants were randomly assigned to either the hypnotic relaxation therapy (HRT) intervention or a no-treatment control arm. Participant eligibility was based on age (at least 18 years), a history of primary breast cancer with no evidence of detectable disease, and the presence of at least 14 hot flashes per week for a period of at least 1 month. Further, participants were restricted to females with a life expectancy of greater than 6 months. Participants were screened for medical and psychological conditions that would preclude study participation. Women who had taken antihormonal agents for breast cancer (e.g., tamoxifen or raloxifene) for more than 1 month were deemed eligible to participate. No other concurrent hormonal or putative therapies, chemotherapy, treatments for hot flashes, or the use of hypnosis for any reason were allowed. Full eligibility criteria were reported by Elkins et al. (2008).
Materials

Numeric visual analog scale for anxiety (NVAAS). A numeric visual analog scale for anxiety rating consisted of a single-item numeric visual analog scale that consists of numbers (0–10) spaced equally and sequentially along a 100 mm horizontal axis on which participants indicate their current level of anxiety. Past research has indicated that this type of scale is an adequate, valid, and reliable measure of anxiety (Davey, Barratt, Butow, & Deeks, 2007; Maxwell, 1978; Williams, Morlock, & Feltner, 2010). A numeric analog scale for anxiety is easy to administer and correlates well with other measures of anxiety ($r = .64, p < .001$, State Trait Anxiety Inventory-State (STAI-S); $r = .46, p < .005$, State Trait Anxiety Inventory-Trait (STAI-T); Elkins, Staniunas, Rajab, Marcus, & Snyder, 2004).

Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A). The HADS-A (Zigmond & Snaith, 1983) consists of seven items. The self-report scale is a measure of participants’ generalized anxiety and fear over the past week. It exhibits high internal consistency ($\alpha = .84–.90$; Julian, 2011) and concurrent validity with other self-report measures of anxiety ($r = \sim .80$ with the General Health Questionnaire (GHQ), Beck’s Depression Inventory (BDI), State Trait Anxiety Inventory (STAI), Clinical Anxiety Scale (CAS), and Symptom Checklist 90 Scale (SCL-90) measures of anxiety; Bjelland et al., 2002).

Stanford Hypnotic Clinical Scale (SHCS). The SHCS (Morgan & Hilgard, 1978) is a five-item measure of hypnotic responsiveness often used as a brief assessment tool in clinical settings (Woody & Barnier, 2008). Administration takes approximately 25 minutes. The SHCS has been shown to be as reliable and valid as other longer measures of hypnotizability (Elkins, 2014a; Morgan & Hilgard, 1978).

Procedure

After obtaining written informed consent, participants randomized to the HRT condition completed a demographic questionnaire and baseline measures (including the HADS-A). A research coordinator scheduled participants for five weekly hypnotic relaxation therapy (HRT) sessions. A numeric analog scale for anxiety was administered before and after each HRT session. The HADS-A was completed at baseline and end-of-study. The SHCS was completed by participants at the end-of-study by masters- or doctoral-level professionals who were not involved in delivery of the intervention. The intervention consisted of HRT for the reduction of hot flashes. HRT is a manualized intervention involving both structured and individualized hypnotic inductions and teaching patients self-hypnosis (Elkins, 2014a). Hypnotic suggestions are targeted to symptom reduction. In the present study, suggestions
were for a hypnotic state, relaxation, and mental imagery for coolness as well as calmness. The hypnotic intervention was delivered according to a treatment manual by a clinician with a doctoral degree in psychology who had completed training according to the guidelines outlined by Elkins and Hammond (1998). HRT for each session included the following: a hypnotic induction; mental imagery for coolness; mental imagery and suggestions for relaxation; deepening hypnosis and dissociation from hot flashes; positive suggestions and imagery for the future; self-hypnosis; and the alert, “In a few moments, return to conscious alertness.” A more detailed description of the procedures has been previously published (Elkins et al., 2008).

Statistical analyses were conducted using SPSS v. 21.0 (IBM Corp, 2012). Student’s dependent samples t tests and a trend analysis were used to analyze pre-to postintervention changes in anxiety for each HRT session and for overall change in anxiety from baseline to follow-up. Bivariate linear regression was used to determine if changes in self-reported anxiety from pre- to postintervention were predictive of overall declines of anxiety reported on the HADS-A. Regression analysis was also used to determine if hypnotizability (SCHS) scores were predictive of reductions in anxiety.

**Results**

Twenty-seven breast-cancer survivors were assigned to receive hypnotic relaxation therapy. Mean age for participants was 55.5 years (SD = 7.3) with a range of 42–60 years. The ethnicity of participants was Caucasian (n = 25) and Hispanic (n = 1). The majority of participants were married (77%) and reported a college education (69%). See Table 1 for complete demographic information. Data were missing on the current measures for 1 participant from the original sample and, therefore, were excluded from the analyses (n = 26). Appendix 1 shows the flow of participants from enrollment through study completion.

The average pretest anxiety score, as reported on a numeric analog scale for anxiety, was 3.83 (SD = 2.11) for the first HRT session. Table 2 summarizes the means and standard deviations of the average numeric analog anxiety scores for all five HRT sessions.

Changes in anxiety reported on a numeric analog scale were assessed for normality and skewed distributions and were found to be normally distributed. In a sample of 26 women, self-reported anxiety significantly decreased from pre- to postintervention, (p < .05; see Table 2). Figure 1 visually illustrates these reductions in self-reported anxiety for each HRT session.

As shown in Figure 2, trend analysis indicated significant declines in pretest anxiety from HRT Session 1 to HRT Session 5, F(1, 125) = 4.06,
Table 1
Demographic Characteristics of HRT Participants

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No.</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>25</td>
<td>96</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High School</td>
<td>8</td>
<td>31</td>
</tr>
<tr>
<td>Bachelor’s degree</td>
<td>8</td>
<td>31</td>
</tr>
<tr>
<td>Master’s degree</td>
<td>10</td>
<td>38</td>
</tr>
<tr>
<td>Marital status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Married</td>
<td>20</td>
<td>77</td>
</tr>
<tr>
<td>Separated</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>11</td>
</tr>
<tr>
<td>Missing data</td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>

Note: Does not include missing participant demographics; n = 26. Mean age = 55 years and 6 months.

Table 2
Comparison of a Numeric Rating Scale for Anxiety Ratings for Female Breast-Cancer Survivors Participating in Hypnotic Relaxation Therapy for Hot Flashes

<table>
<thead>
<tr>
<th></th>
<th>Preintervention</th>
<th>Postintervention</th>
<th>Analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Session 1</td>
<td>3.83</td>
<td>2.11</td>
<td>0.77</td>
</tr>
<tr>
<td>Session 2</td>
<td>3.27</td>
<td>1.89</td>
<td>0.65</td>
</tr>
<tr>
<td>Session 3</td>
<td>3.31</td>
<td>2.41</td>
<td>0.83</td>
</tr>
<tr>
<td>Session 4</td>
<td>3.38</td>
<td>2.16</td>
<td>0.54</td>
</tr>
<tr>
<td>Session 5</td>
<td>2.44</td>
<td>2.00</td>
<td>0.40</td>
</tr>
</tbody>
</table>

Note. Statistics are based on two-tailed dependent-samples t tests using the Welch procedure for unequal variances. The sample size for each analysis was n = 26. CI = confidence interval.
*p < .001.

p = .046. A dependent-samples t test of pretest anxiety for HRT Session 1 and HRT Session 5 was statistically significant, t(25) = 2.57, p = .016, d = 0.50, Mean difference = 1.38, 95% CI [.277, 2.49]. Trend analysis of posttest anxiety ratings from HRT Session 1 to HRT Session 5 showed reductions yet were not found to be statistically significant, F(1, 125) = 2.05, p = .099 (see Figure 2).

As Elkins et al. (2008) previously reported, HADS-A scores reduced significantly among participants receiving the intervention,
Figure 1. Reductions in anxiety following HRT sessions.

Figure 2. Trends in anxiety reduction for five weekly sessions of HRT.

\[ F(2, 44) = 6.083, p < .005, \eta^2 = .217. \] Findings from the current study provide further support for reductions in HADS-A scores among 26 participants receiving five weekly sessions of HRT (Baseline Mean = 5.89, SD = 4.34; Endpoint Mean = 3.23, SD = 3.19, \( p < .004 \)). A regression analysis of these participants showed declines in self-reported anxiety pre- to postintervention were predictive of anxiety reductions on the HADS-A from baseline to endpoint, \( R^2 = .15, p < .05 \).

Hypnotizability as measured by the SCHS was analyzed as a possible moderator of change in self-reported anxiety. A bivariate regression
analysis showed hypnotizability did not significantly predict for reductions in self-reported anxiety from pre- to postintervention, $R^2 = .022$, $F(1, 23) = 0.51, p = .48$, or as reported on the HADS-A, $R^2 = .004, p = .77$. Data were missing for 1 participant on the SHCS and were excluded from the analyses ($n = 25$). The intervention was well tolerated and there were no adverse events (Elkins et al., 2008).

**Discussion**

Anxiety is common among breast-cancer survivors (Prokop, Bradley, Burish, Anderson, & Fox, 1991). Anxiety disrupts and decreases quality of life, thereby becoming a barrier to complete recovery (Stark & House, 2000). As rates of breast cancer increase, it is imperative that treatments be developed that address the negative sequelae of cancer diagnosis, treatment, and survivorship, including anxiety (Kahn, Ward, Watson, & Rose, 2010; Lebel et al., 2013). Research has shown breast-cancer survivors are receptive to complementary therapies, such as mind-body therapies, and seek them out to counteract the accompanying side effects of cancer treatment and recovery (Hann, Baker, Denniston, & Entrekin, 2005; Matthews, Sellergren, Huo, List, & Fleming, 2007).

The present analysis provides data to support that hypnotic relaxation therapy (HRT) may be useful in reducing self-reported anxiety among breast-cancer survivors. Using hypnosis to treat anxiety among breast-cancer patients is an attractive option in that it poses little risk to the patient, has low patient burden and is cost effective. Hypnosis is usually reported as a pleasant experience, has few (if any) known side effects and does not interact with medications. Additionally, once a patient becomes familiar with hypnosis, it may be generalized to help with other distressing symptoms.

The effect sizes in this study were found to be large, but it has been reported that the use of a pretest-posttest design, such as that used in this study, may inflate effect sizes (Matt & Navarro, 1997). Also, future research utilizing objective physiological measures of anxiety are needed to fully verify the anxiety-reducing capabilities of HRT (Vande Vusse, Hanson, Berner, & White Winters, 2010).

Although the effects of HRT show promise for the reduction of anxiety among breast-cancer survivors, larger randomized controlled studies are needed to determine if these results are robust. Also, because the HRT in the current study was specifically intended to address hot flashes, further investigation is warranted to better understand if anxiety reductions were independent of the reductions in hot flashes also experienced by participants receiving HRT. A future study should consider anxiety as the primary measure, both subjectively and objectively.
and should include an active control group, such as structured attention, thereby providing control for attention, time, self-report bias, and other demand characteristics that could confound results.

Although hypnotizability has been found to moderate the effect of hypnosis on hot flashes (Elkins et al., 2011), in the present study, it did not moderate reductions in anxiety among breast-cancer survivors. In the present study, HRT was effective in reducing anxiety regardless of hypnotic ability. Although hypnotizability may play a role in altering a physical symptom (such as hot flashes), reduction of emotional symptoms (such as anxiety) may be largely dependent on relaxation. It is noteworthy that declines in self-reported anxiety pre- to postintervention were predictive of anxiety reductions as measured on the HADS-A. This suggests that the initial response to hypnotic induction with reduction in anxiety may be a positive indicator of later endpoint reduction in self-reported anxiety.

There is a need for effective treatments of anxiety among breast-cancer survivors that have low patient burden and are cost effective and safe. Hypnotic relaxation therapy shows promise as such a treatment; yet, more randomized controlled trials are needed before definitive conclusions can be drawn. In order to provide the best care possible to those recovering from the effects of breast cancer, it is imperative that these treatments be researched and developed further so that they may be disseminated to those in need of them.

**Funding**

Supported by Grant No. R21 CA100594-01 from the National Cancer Institute and Grant No. U01 AT004634-02 from the National Center for Complementary and Integrative Medicine, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**References**


Angstreduktion bei Brustkrebsüberlebenden, die hypnotische Entspannungstherapie gegen Hitzewallungen erhielten

Alisa J. Johnson, Joel Marcus, Kimberly Hickman, Debra Barton, und Gary Elkins


**Stephanie Reigel, MD**

Réduction de l’anxiété chez les survivantes d’un cancer du sein suivant une thérapie de relaxation hypnotique pour soulager les bouffées de chaleur

Alisa J. Johnson, Joel Marcus, Kimberly Hickman, Debra Barton et Gary Elkins

Johanne Reynault
C. Tr. (STIBC)

Reducción de ansiedad en sobrevivientes de cáncer de mama bajo tratamiento hipnótico de relajación para bochornos

Alisa J. Johnson, Joel Marcus, Kimberly Hickman, Debra Barton, y Gary Elkins

Resumen: La ansiedad es común en sobrevivientes de cáncer de mama. Este análisis examinó el efecto de una terapia hipnótica de relajación, desarrollada para reducir bochornos en niveles de ansiedad en sobrevivientes de cáncer de mama. La ansiedad se evaluó mediante una escala numérica análoga y la subescala de ansiedad de la Escala de Ansiedad y Depresión Hospitalaria. Se encontraron reducciones significativas entre el pre y post-intervención para cada sesión semanal y fueron predictivas de las reducciones totales de ansiedad de la línea basal hasta el final de la última intervención. En este análisis, la hipnotizabilidad no predijo significativamente las reducciones de ansiedad medidas antes y después de cada sesión ni de la línea basal al término del tratamiento. Estos datos proveen sustento inicial para el uso de la terapia de relajación hipnótica para reducir ansiedad entre sobrevivientes de cáncer de mama.

Omar Sánchez-Armáss Cappello
Autonomous University of San Luis Potosí, Mexico
Appendix 1: Flow Diagram of Participant Enrollment

Enrollment

Assessed for eligibility (n = 86)

- Excluded (n = 26)
  - Did not meet inclusion criteria or declined to participate

Randomized (n = 60)

Allocation

- Allocated to waitlist control (n = 30)
  - Received waitlist control (n = 30)
- Allocated to intervention (n = 30)
  - Received allocated intervention (n = 30)

Follow-Up

- Discontinued (n = 6)
  - Reasons included: being too busy/no desire to continue for personal reasons, not able to be reached
- Lost to follow-up (n = 3)
  - Reasons included: being too busy/no desire to continue for personal reasons, not able to be reached

Analysis

- Analysed in full study, (Elkins et al., 2008) (n = 24)
- Analysed in current study (n = 26)
  - Excluded from current analyses, (n = 1, missing data)
- Analysed in full study, (Elkins et al., 2008) (n = 27)

Flow diagram template courtesy of Schulz et al. (2010).